Condition: Cervix Uteri Cancer · Sponsor: Tehran University of Medical Sciences
Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.
This description comes directly from the study's public registry record.
Kasra Kolahdouzan, M.D. · +989144083785 · k-kolahdouzan@razi.tums.ac.ir
Ebrahim Esmati, M.D. · +989126880306 · eb_esmati@yahoo.com
Always discuss trial participation with your own doctor first.
| Imam Khomeini Hospital Complex | Tehran, Iran | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04831437